Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

Actinogen Medical (ASX:ACW): Will history repeat itself? Can it bounce back from a troublesome Phase 2 trial?

Actinogen Medical (ASX:ACW) is the poster child for how volatile biotech stocks can be. the last time we wrote about this company was in August last year when shares more than halved after results of a Phase II trial that investors perceived to be a flop. But the company has soldiered on and has a…

ByNick SundichSeptember 9, 2025

Imricor Medical Systems (ASX:IMR): Is it the dark horse in the ASX medtech sector?

Imricor Medical Systems (ASX:IMR) is one of a handful of radiology stocks on the ASX, seeking to emulate the success of Pro Medicus (ASX:PME). There's no shortage of peers including Curvebeam AI (ASX:CVB), Resonance Health (ASX:RHT) and 4D Medical (ASX:4DX). But Imricor just might be the dark horse and we're going to tell you why. What…

ByNick SundichSeptember 8, 2025

Argenica Therapeutics (ASX: AGN): A 60% Crash or a Second Chance?

Argenica Therapeutics Just Faced Its Toughest Test — What Comes Next Argenica Therapeutics Ltd (ASX: AGN) has been thrown into the spotlight after its phase 2 trial results for ARG-007 sparked a brutal sell-off, sending the share price tumbling more than 60 percent in a single day. For investors, that kind of market reaction is…

ByCharlie YouldenSeptember 3, 2025

4D Medical (ASX:4DX) could become the next Pro Medicus, and its taken some important strides in 2025!

There's not many Australian radiology companies that seek to conquer the USA, but 4D Medical (ASX:4DX) is one of them. Another one was Pro Medicus (ASX:PME), and everyone knows how that story turned out - that stock is now worth over $11bn, all because of runaway success in the US market. 4D Medical shareholders inevitably…

ByNick SundichSeptember 2, 2025

ASX stocks in America: Here are 4 performing well and 4 performing poorly

You might think ASX stocks in America are doing better than peers which are not there because the USA is a much bigger market. In reality, this is not always the case. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"][/sg_popup] ASX stocks in America: Here are 4 performing…

ByNick SundichSeptember 2, 2025

Blinklab (ASX:BB1): Is this exciting company the next ResApp?

Blinklab (ASX:BB1) is the answer to the question of how you could help children with autism - a response that begins with 'there's an app for that'. There is precedent for app-based health companies to succeed, just look at ResApp (ASX:RAP), which was bought by Pfizer for $179m back in 2022. The former chairman of that…

ByNick SundichAugust 29, 2025

Why Telix (ASX:TLX) Fell 20% After FDA News – And What Investors Should Know

When expectations fall short, sentiment can shift in an instant. That is exactly what happened with Telix Pharmaceuticals (ASX: TLX) after the company received an unexpected setback from the U.S. Food and Drug Administration. TLX had applied for approval of TLX250-CDx, an innovative imaging agent designed to help doctors more accurately diagnose kidney…

ByCharlie YouldenAugust 28, 2025

Galidesivir has made Island Pharmaceuticals the ultimate ‘America First’ play for ASX investors!

Think of 'America First' ASX stocks and Island Pharmaceuticals (ASX:ILA) typically hasn't come to mind, but its acquisition of Galidesivir should put it firmly in the list. You cannot question the data that the company is in possession of, but some investors may think a company with plans to undertake an 'animal study' is years…

ByNick SundichAugust 27, 2025

Nova Eye Medical (ASX:EYE) has been on a strong run, up 50% in one month. Is there more upside?

Nova Eye Medical (ASX:EYE) is no clinical stage medtech company, but has just an exciting 12 months ahead as if it was a clinical stage company with company-making catalysts ahead. Because even though it has commercialised its devices, a major 12 months are ahead during which it is expected to make major inroads in the US…

ByNick SundichAugust 27, 2025

Here are 5 ASX biotechs expecting clinical trial results in the next few months!

Here are 5 ASX biotechs expecting clinical trial results in the next few months! Dimerix (ASX:DXB) Dimerix is in the middle of a Phase III trial or its DMX-200 drug for a condition known as Focal Segmental Glomerulosclerosis (FSGS). For patients with FSGS, the kidneys’ ability to purify (clean) the blood is impaired. This can…

ByNick SundichAugust 27, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Actinogen Medical (ASX:ACW): Will history repeat itself? Can it bounce back from a troublesome Phase 2 trial?

Imricor Medical Systems (ASX:IMR): Is it the dark horse in the ASX medtech sector?

Argenica Therapeutics (ASX: AGN): A 60% Crash or a Second Chance?

4D Medical (ASX:4DX) could become the next Pro Medicus, and its taken some important strides in 2025!

ASX stocks in America: Here are 4 performing well and 4 performing poorly

Blinklab (ASX:BB1): Is this exciting company the next ResApp?

Why Telix (ASX:TLX) Fell 20% After FDA News – And What Investors Should Know

Galidesivir has made Island Pharmaceuticals the ultimate ‘America First’ play for ASX investors!

Nova Eye Medical (ASX:EYE) has been on a strong run, up 50% in one month. Is there more upside?

Here are 5 ASX biotechs expecting clinical trial results in the next few months!

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here